BioXcel Blog Innovation in the treatment of Neurofibromatosis type 2 (NF2) tumors

In neuro-oncology, our first product BXCL101, is a proteasomal inhibitor being developed for its use in patients suffering from Neurofibromatosis type 2. NF2 is a benign tumor prone hereditary condition which is mostly associated with bilateral vestibular schwannomas and affects the auditory-vestibular nerves. With its unique mechanism of action, BXCL101 stabilizes the tumor suppressor genes ... Continue reading Innovation in the treatment of Neurofibromatosis type 2 (NF2) tumors